Luteinising hormone releasing hormone analogues in the treatment of prostate cancer

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 12, 2002, Pages 1685-1692

  Gommersall, Lyndon M ^a   Hayne, Dickon ^b   Shergill, Iqbal S ^a   Arya, Manit ^a   Wallace, D M A ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b Institute of Urology   (United Kingdom)

Author keywords

Androgen blockade; Buserelin; De capeptyl; FSH; GNRH; Goserelin; Leuproprelin; LH; LHRH analogues; Prostap; Prostatic neoplasms; Triptorelin; Tumour flare; Zoladex

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; CYPROTERONE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; PROSTAP 3; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN; ZOLADEX LA;

ADVANCED CANCER; BONE DENSITY; BONE MINERAL; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG TOLERABILITY; GYNECOMASTIA; HOT FLUSH; HUMAN; INJECTION; LETHARGY; LIBIDO DISORDER; MALE; MASTALGIA; METASTASIS; NONHUMAN; ORCHIECTOMY; PROSTATE CANCER; RECEPTOR BLOCKING; REVIEW; THROMBOEMBOLISM;

EID: 12244306215     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.12.1685     Document Type: Review

References (57)

1. MORRIS MJ, SCHER HI: Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. Surg. Oncol. (2002) 11:13-23.
2. MAJEED A, BABB P, JONES J, QUINN M: Trends in prostate cancer incidence, mortality and survival in England and Wales (1971-1998). BJU Int. (2000) 85:1058-1062.
3. PALMER JF: The Works of John Hunter F.R.S. with notes. Longman, London, UK (1837).
4. WHITE WJ: Surgical removal of the hypertrophied prostate. Ann. Surg. (1893):152.
5. DEMING CL, JENKINS RH, VAN WAGENER G: Further studies in the endocrinology relationships of prostatic hypertrophy. J. Urol. (1935):34.
6. MOORE RA, MCCLELLAN AM: Histological study of the effect of the sex hormones on the human prostate. J. Urol. (1938) 40:641.
7. HUGGINS C, STEPHENS RA: The effects of castration on benign hypertrophy of the prostate in man. J. Urol. (1940) 43:105.
8. STAMEY TA, YANG N, HAY AR, MCNEAL JE, FREIHA FS, REDWINE E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. (1987) 317:909-916.
9. ABRAHAMSSON PA: Treatment of locally advanced prostate cancer - a new role for antiandrogen monotherapy? Eur. Urol. (2001) 39(Suppl. 1):22-28.
10. HUGGINS CB, HODGES CV: Studies on Prostate Cancer: 1. The effects of castration, of eostrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. (1941) 1:203.
11. HUGGINS C, STEPHENS RC, HODGES CV: Studies on prostate cancer: 2. The effects of castration on advanced carcinoma of the prostate. Arch. Surg. (1941) 43:209.
12. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg. Gynecol. Obstet. (1967) 124:1011-1017.
13. VOGELZANG NJ, CHODAK GW, SOLOWAY MS et al.: Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology (1995) 46:220-226.
14. LABRIE F, BELANGER A, CUSAN L et al.: Antifertility effects of LHRH agonists in the male. J. Androl. (1980) 1:209-228.
15. JONES TH, JUSTICE S, PRICE A, CHAPMAN K: Interleukin-6 secreting human pituitary adenomas in vitro. J. Clin. Endocrinol. Metab. (1991) 73:207-209.
16. TOLIS G, ACKMAN D, STELLOS A et al.: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc. Natl. Acad. Sci. USA (1982) 79:1658-1662.
17. WAYMONT B, LYNCH TH, DUNN JA et al.: Phase III randomised study of Zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br. J. Urol. (1992) 69:614-620.
18. SCHALLY AV, COMARU-SCHALLY AM, PLONOWSKI A, NAGY A, HALMOS G, REKASI Z: Peptide analogs in the therapy of prostate cancer. Prostate (2000) 45:158-166.
19. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N. Engl. J. Med. (1984) 311:1281-1286.
20. LABRIE F: Intracrinology. Mol. Cell Endocrinol. (1991) 78:C113-C118.
21. STEINBERG GD, ISAACS JT: Pharmacological approaches to the management of metastatic prostatic cancer. In: Cancer Chemotherapy (Hickman JA & Hitton TR, Eds). Blackwell Scientific Publications, Oxford, UK (1993):322-341.
22. VARENHORST E, WALLENTIN L, CARLSTROM K: The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand. J. Urol. Nephrol. (1982) 16:31-36.
23. Prostate cancer and gonadorelin analogues: 8.3.4.2. Brit. National Formulary 43 (2002).
24. BAUS Section of Oncology. Analyses of minimum data set for urological cancers January 1st - 31st December 2000. The British Association of Urological Surgeons (2001).
25. Prescription cost analysis data (England 2001). Department of Health, UK (2001).
26. BEESE G: Randomised cross over trial to assess the tolerability of LHRH analogue administration. British Association of Urological Nurses Annual General Meeting (2000).
27. SMALL EJ: Prostate cancer, incidence, management and outcomes. Drugs Aging (1998) 13:71-81.
28. DIJKMAN GA, DEBRUYNE FM, FERNANDEZ DM et al.: A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group. Eur. Urol. (1995) 27:43-46.
29. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet (2000) 355:1491-1498.
30. COCKSHOTT ID: Clinical pharmacokinetics of goserelin. Clin. Pharmacokinet. (2000) 39:27-48.
31. PERREN TJ, CLAYTON RN, BLACKLEDGE G et al.: Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI (1186)30 (Zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer. Cancer Chemother. Pharmacol. (1986) 18:39-43.
32. AHMANN FR, CITRIN DL, DEHAAN HA et al.: Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. J. Clin. Oncol. (1987) 5:912-917.
33. JOHNS WD, GARNICK MB, KAPLAN WD: Leuprolide therapy for prostate cancer. An association with scintigraphic 'flare' on bone scan. Clin. Nucl. Med. (1990) 15:485-487.
34. SMITH JA Jr: Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue. Prog. Clin. Biol. Res. (1985) 185A:279-285.
35. LABRIE F, DUPONT A, BELANGER A, LACHANCE R: Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J. Urol. (1987) 138:804-806.
36. LABRIE F, DUPONT A, BELANGER A, EMOND J, MONFETTE G: Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc. Natl. Acad. Sci. USA (1984) 81:3861-3863.
37. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with (3283) deaths in (5710) patients. Prostate Cancer Trialists' Collaborative Group. Lancet (1995) 346:265-269.
38. CAUBET JF, TOSTESON TD, DONG EW et al.: Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology (1997) 49:71-78.
39. SEIDENFELD J, SAMSON DJ, HASSELBLAD V et al.: Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann. Intern. Med. (2000) 132:566-577.
40. SAROSDY MF, SCHELLHAMMER PF, SOLOWAY MS et al.: Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int. (1999) 83:801-806.
41. CHODAK GW, VOGELZANG NJ, CAPLAN RJ, SOLOWAY M, SMITH JA: Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA (1991) 265:618-621.
42. Prostate cancer and gonadorelin analogues: 8.3.4.2. Brit. National Formulary 43 (2002).
43. IVERSEN P, TYRRELL CJ, KAISARY AV et al.: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J. Urol. (2000) 164:1579-1582.
44. TYRRELL CJ: Gynaecomastia: aetiology and treatment options. Prost. Cancer. Prost. Dis. (1999) 2:167.
45. DENIS LJ, KEUPPENS F, SMITH PH et al.: Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur. Urol. (1998) 33:144-151.
46. BOLLA M, GONZALEZ D, WARDE P et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. (1997) 337:295-300.
47. PILEPICH MV, WINTER K, JOHN MJ et al.: Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. (2001) 50:1243-1252.
48. LILLEBY W, FOSSA SD, KNUTSEN BH, ABILDGAARD A, SKOVLUND E, LIEN HH: Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation. Radiother. Oncol. (2000) 57:195-200.
49. KUCWAY R, VICINI F, HUANG R, STROMBERG J, GONZALEZ J, MARTINEZ A: Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J. Urol. (2002) 167:2443-2447.
50. DEBRUYNE FM, WITJES WP: Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. Mol. Urol. (2000) 4:251-256.
51. THEYER G, HAMILTON G: Current status of intermittent androgen suppression in the treatment of prostate cancer. Urology (1998) 52:353-359.
52. ABRAHAMSSON PA: Intermittent androgen suppression. Too good to be true? Scand. J. Urol. Nephrol. Suppl. (1999) 203:45-49.
53. EGAWA S, TAKASHIMA R, MATSUMOTO K, MIZOGUCHI H, KUWAO S, BABA S: A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men. Jpn. J. Clin. Oncol. (2000) 30:21-26.
54. GONCALVES F, MIKLOSI M, BREZA J: Intermittent androgen suppression for locally advanced and metastatic prostate cancer. Eur. Urol. (2000) 38(4):503.
55. KAISARY AV, TYRRELL CJ, PEELING WB, GRIFFITHS K: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br. J. Urol. (1991) 67:502-508.
56. DANIELL HW, DUNN SF, FERGUSON DW, LOMAS G, NIAZI Z, STRATTE PT: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. Urol. (2000) 163:181-186.
57. WEI JT, GROSS M, JAFFE CA et al.: Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology (1999) 54:607-611.